Last edition
News about Global Pharma
Ichnos Glenmark Innovation Secures USD 700M Upfront in AbbVie Licensing Deal for ISB 2001
Ichnos Glenmark Innovation (IGI) has received an upfront payment of USD 700 million from AbbVie under the terms of their recently announced global licensing agreement for IGI’s lead investigational asset, ISB 2001.
Global Pharma | 09/09/2025 | By Dineshwori | 302
Indegene Expands India Footprint with New Centre in Pune
Indegene, a digital-first life sciences commercialisation company, has expanded its India footprint with the launch of a new centre in Pune.
Global Pharma | 08/09/2025 | By Mrinmoy Dey | 191
Servier to Acquire KER-0193 from Kaerus Bioscience in Deal Worth Up to USD 450 Million
Servier has signed a definitive agreement to acquire KER-0193 from Kaerus Bioscience, a potential first-in-disease treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder.
Global Pharma | 08/09/2025 | By Mrinmoy Dey | 238
Ronovo Surgical Closes Series D Financing
Ronovo Surgical secures USD 67 million in Series D funding led by JJDC, raising over USD 100 million in 2025 to advance minimally invasive surgery.
Global Pharma | 06/09/2025 | By Dineshwori | 201
Hengrui Pharma Grants Braveheart Bio Exclusive Global Rights to Cardiac Myosin Inhibitor HRS-1893
Hengrui Pharma has signed an exclusive licensing deal with US-based Braveheart Bio for its Phase 3-ready cardiac myosin inhibitor HRS-1893. Braveheart will make an upfront payment of USD 65 million and a near-term payment of up to USD 10 million upon technology transfer completion, totalling USD 75 million.
Global Pharma | 06/09/2025 | By Mrinmoy Dey | 536
Clearpoint Prism Neuro Laser Therapy System Receives FDA Clearance for 1.5T MRI Use
ClearPoint Neuro has announced that its ClearPoint Prism Neuro Laser Therapy System has received 510(k) clearance from the US FDA for use under 1.5T MRI guidance, in addition to its previously cleared 3T MRI compatibility.
Global Pharma | 06/09/2025 | By Dineshwori | 444
Cipla launches HUENA, maiden non-antibiotic drug in India for recurring UTIs
With HUENA, Cipla becomes the first in India to offer Methenamine Hippurate, a non-antibiotic therapy for recurrent UTIs, strengthening its fight against AMR.
Global Pharma | 06/09/2025 | By Dineshwori | 142
Arrowhead and Novartis Sign Global License and Collaboration Deal
Novartis secures exclusive global rights to Arrowhead’s ARO-SNCA therapy for Parkinson’s and related disorders, with Arrowhead receiving USD 200 million upfront.
Global Pharma | 05/09/2025 | By Dineshwori | 240
Argo Biopharma and Novartis Partner on Novel Cardiovascular Therapies
Argo to receive $160 million upfront as Novartis licenses pipeline assets, explores ANGPTL3 in dyslipidemia, and secures options for future siRNA candidates.
Global Pharma | 05/09/2025 | By Dineshwori | 334
Syantra, Inc., a cancer diagnostics innovator, has launched a new therapeutic division aimed at developing first-in-class immuno-oncology therapies to reprogram tumour-affected immune cells and restore anti-cancer immunity.
Global Pharma | 05/09/2025 | By Mrinmoy Dey | 122
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy